404 related articles for article (PubMed ID: 19768638)
21. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
22. Cost associated with the treatment of influenza in a managed care setting.
Cox F; Khan ZM; Schweinle JE; Okamoto L; McLaughlin T
MedGenMed; 2000 Oct; 2(4):E34. PubMed ID: 11104480
[TBL] [Abstract][Full Text] [Related]
23. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of improving primary care treatment of late-life depression.
Katon WJ; Schoenbaum M; Fan MY; Callahan CM; Williams J; Hunkeler E; Harpole L; Zhou XH; Langston C; Unützer J
Arch Gen Psychiatry; 2005 Dec; 62(12):1313-20. PubMed ID: 16330719
[TBL] [Abstract][Full Text] [Related]
25. Economic burden of rhinitis in managed care: a retrospective claims data analysis.
Dalal AA; Stanford R; Henry H; Borah B
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):23-9. PubMed ID: 18681080
[TBL] [Abstract][Full Text] [Related]
26. Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.
Insinga RP; Ng-Mak DS; Hanson ME
Cephalalgia; 2011 Nov; 31(15):1570-5. PubMed ID: 22013140
[TBL] [Abstract][Full Text] [Related]
27. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.
Ladapo JA; David G; Gunnarsson CL; Hao SC; White SA; March JL; Reynolds MR
J Cardiovasc Electrophysiol; 2012 Jan; 23(1):1-8. PubMed ID: 21777324
[TBL] [Abstract][Full Text] [Related]
28. Burden of illness of hepatitis C from a managed care organization perspective.
Armstrong EP; Charland SL
Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
[TBL] [Abstract][Full Text] [Related]
29. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
30. Health service utilization among Alzheimer's disease patients: evidence from managed care.
Frytak JR; Henk HJ; Zhao Y; Bowman L; Flynn JA; Nelson M
Alzheimers Dement; 2008 Sep; 4(5):361-7. PubMed ID: 18790463
[TBL] [Abstract][Full Text] [Related]
31. The burden of atrial fibrillation on the hospital sector in Canada.
O'Reilly DJ; Hopkins RB; Healey JS; Dorian P; Sauriol L; Tarride JE; Burke N; Goeree RA
Can J Cardiol; 2013 Feb; 29(2):229-35. PubMed ID: 22652091
[TBL] [Abstract][Full Text] [Related]
32. The economic burden of intracerebral hemorrhage: evidence from managed care.
Russell MW; Boulanger L; Joshi AV; Neumann PJ; Menzin J
Manag Care Interface; 2006 Jun; 19(6):24-8, 34. PubMed ID: 16892657
[TBL] [Abstract][Full Text] [Related]
33. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
34. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting.
Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A
Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344
[TBL] [Abstract][Full Text] [Related]
35. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
36. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
37. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
38. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
39. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
40. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective.
Lee WC; Lamas GA; Balu S; Spalding J; Wang Q; Pashos CL
J Med Econ; 2008; 11(2):281-98. PubMed ID: 19450086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
